Gilead Acquires TREX1 Program from Sprint Bioscience for ~$414M

Shots: Sprint Bioscience has reported the sale of its TREX1 cancer program to Gilead Sciences As per the Deal, Sprint Bioscience will receive $14M upfront and up to $400M in clinical, regulatory, and commercial milestones TREX1 program has demonstrated notable potential in the pre-clinical stage Ref: Sprint Bioscience | Image: Gilead & Sprint Bioscience | Press…

ByRidhi RastogiNovember 25, 2025

NEWS

GE HealthCare to Acquire Intelerad for $2.3B

Shots: GE HealthCare has entered into an agreement to acquire Intelerad, expanding its cloud-enabled & AI-powered solutions portfolio As per the deal, GE HealthCare will acquire Intelerad for a purchase price of $2.3B in cash; closing is expected in H1’26 Acquisition will add Intelerad’s cloud-enabled radiology & cardiology imaging platforms & outpatient enterprise workflow solutions…

ByRidhi RastogiNovember 21, 2025

NEWS

Abbott Expands Leadership in Cancer Diagnostics with ~$23B Acquisition of Exact Sciences

Shots: Abbott has entered into a definitive agreement to acquire Exact Sciences, making Exact a subsidiary of Abbott upon deal completion As per the deal, Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of ~$21B & an estimated enterprise value of $23B, with financing that includes absorbing Exact’s ~$1.8B in…

ByRidhi RastogiNovember 21, 2025

NEWS

J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Shots: J&J has entered into a definitive agreement to acquire Halda Therapeutics, strengthening its oncology pipeline As per the deal, J&J will acquire Halda for $3.05B in cash, with the deal treated as a business combination & expected to close in the coming months Acquisition will add Halda’s Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform…

ByRidhi RastogiNovember 18, 2025

NEWS

Day One Biopharmaceuticals to Acquire Mersana Therapeutics for ~$285M

Shots: Day One has entered into a definitive merger agreement to acquire Mersana, delisting Mersana from the public market & making it a wholly owned subsidiary upon deal completion As per the deal, Day One will acquire Mersana for $25/share plus a CVR of ~$30.25/share tied to certain clinical development, regulatory, & commercial milestones for…

ByRidhi RastogiNovember 13, 2025

NEWS

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Shots: Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decade Sandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform…

ByDipanshu DixitNovember 5, 2025

NEWS

Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement

Shots: Metsera has declared Novo Nordisk’s unsolicited ~$9B acquisition proposal, valuing shares up to $77.75, as a “Superior Company Proposal” than its existing Pfizer Merger Agreement The 2-step proposal incl. an initial $56.5/share cash payment & issuance of non-voting preferred stock for 50% of Metsera’s share capital, followed by a CVR of ~$21.25/share in cash…

ByRidhi RastogiOctober 31, 2025

NEWS

Thermo Fisher Scientific to Acquire Clario for ~$9.4B

Shots: Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after…

ByRidhi RastogiOctober 29, 2025

NEWS

Eli Lilly Strengthens its Gene Therapy Capabilities with Adverum Acquisition

Shots: Eli Lilly has entered into a definitive agreement to acquire Adverum Biotechnologies, incl. its asset Ixo-vec As per the deal, Lilly will acquire Adverum for $3.56/share plus a CVR of ~$8.91 per share, tied to milestones: for ~$1.78 per CVR on Ixo-vec’s FDA approval within 7yrs. of closing & ~$7.13 per CVR upon achieving $1B…

ByRidhi RastogiOctober 27, 2025

NEWS

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Shots: Novartis has agreed to acquire Avidity Biosciences, strengthening its neuroscience pipeline with Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform & 3 late-stage programs As per the deal, Novartis will acquire Avidity for $72/share, valuing the company at ~$12B with an enterprise value of ~$11B; closing expected in H1’26 Before the merger, Avidity will transfer its early-stage precision…

ByRidhi RastogiOctober 27, 2025

Gilead Acquires TREX1 Program from Sprint Bioscience for ~$414M

GE HealthCare to Acquire Intelerad for $2.3B

Abbott Expands Leadership in Cancer Diagnostics with ~$23B Acquisition of Exact Sciences

J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Day One Biopharmaceuticals to Acquire Mersana Therapeutics for ~$285M

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement

Thermo Fisher Scientific to Acquire Clario for ~$9.4B

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Contact US

OUR INFORMATION

FOLLOW US